Resumé
Background: Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury. Nowadays, aHUS is successfully treated with eculizumab, a humanized, chimeric IgG2/4 kappa antibody, which binds human complement C5 and blocks generation of C5a and membrane-attack-complex. Case presentation: A 25-year-old woman with end stage renal disease due to relapsing atypical hemolytic uremic syndrome had a relapse of the disease during pregnancy. She was treated with eculizumab. We measured reduced formation of the membrane-attack complex in newborn's umbilical cord vein blood using the sensitive and specific Palarasah-Nielsen-ELISA. Conclusions: Eculizumab treatment of the mother with end stage renal disease may cause reduced innate immunity which could render newborns more susceptible to infections.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 307 |
| Tidsskrift | BMC Nephrology |
| Vol/bind | 20 |
| Antal sider | 5 |
| ISSN | 1471-2369 |
| DOI | |
| Status | Udgivet - 7. aug. 2019 |
Fingeraftryk
Citer dette
}
Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother : A case report. / Nagarajah, Subagini; Tepel, Martin; Nielsen, Christian; Assing, Kristian; Palarasah, Yaseelan; Andersen, Lise Lotte Torvin; Lange, Lotte Borg; Bistrup, Claus.
I: BMC Nephrology, Bind 20, 307, 07.08.2019.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
TY - JOUR
T1 - Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother
T2 - A case report
AU - Nagarajah, Subagini
AU - Tepel, Martin
AU - Nielsen, Christian
AU - Assing, Kristian
AU - Palarasah, Yaseelan
AU - Andersen, Lise Lotte Torvin
AU - Lange, Lotte Borg
AU - Bistrup, Claus
PY - 2019/8/7
Y1 - 2019/8/7
N2 - Background: Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury. Nowadays, aHUS is successfully treated with eculizumab, a humanized, chimeric IgG2/4 kappa antibody, which binds human complement C5 and blocks generation of C5a and membrane-attack-complex. Case presentation: A 25-year-old woman with end stage renal disease due to relapsing atypical hemolytic uremic syndrome had a relapse of the disease during pregnancy. She was treated with eculizumab. We measured reduced formation of the membrane-attack complex in newborn's umbilical cord vein blood using the sensitive and specific Palarasah-Nielsen-ELISA. Conclusions: Eculizumab treatment of the mother with end stage renal disease may cause reduced innate immunity which could render newborns more susceptible to infections.
AB - Background: Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury. Nowadays, aHUS is successfully treated with eculizumab, a humanized, chimeric IgG2/4 kappa antibody, which binds human complement C5 and blocks generation of C5a and membrane-attack-complex. Case presentation: A 25-year-old woman with end stage renal disease due to relapsing atypical hemolytic uremic syndrome had a relapse of the disease during pregnancy. She was treated with eculizumab. We measured reduced formation of the membrane-attack complex in newborn's umbilical cord vein blood using the sensitive and specific Palarasah-Nielsen-ELISA. Conclusions: Eculizumab treatment of the mother with end stage renal disease may cause reduced innate immunity which could render newborns more susceptible to infections.
KW - Atypical hemolytic uremic syndrome
KW - Complement
KW - Eculizumab
KW - End-stage renal disease
KW - Membrane-attack complex
KW - Pregnancy
KW - Umbilical cord vein blood
U2 - 10.1186/s12882-019-1469-9
DO - 10.1186/s12882-019-1469-9
M3 - Journal article
C2 - 31390992
AN - SCOPUS:85071949106
VL - 20
JO - B M C Nephrology
JF - B M C Nephrology
SN - 1471-2369
M1 - 307
ER -